Table 2. Pathways affected by differentially expressed genes (FDR ≤ 0.05, absolute fold change ≥ 2).

Name	P-value	Overlap/no. of molecules
Top canonical pathways affected by VitC
Hepatic Fibrosis/Hepatic Stellate Cell Activation	5.61E–06	9.8% 18/183
Mitotic Roles of Polo-Like Kinase	1.05E–04	13.6% 9/66
Acute Phase Response Signaling	3.73E–04	8.3% 14/169
Cell Cycle: G2/M DNA Damage Checkpoint Regulation	4.59E–04	14.3% 7/49
Salvage Pathways of Pyrimidine Ribonucleotides	1.60E–03	9.5% 9/95
Diseases and disorders affected by VitC
Cancer	2.57E–04–3.31E–16	565
Organismal Injury and Abnormalities	2.62E–04–3.31E–16	582
Reproductive System Disease	2.24E–04–3.53E–16	333
Gastrointestinal Disease	2.62E–04–4.33E–13	499
Dermatological Diseases and Conditions	1.01E–04–9.62E–11	380
Molecular and cellular functions affected by VitC
Cellular Assembly and Organization	2.68E–04–2.88E–14	122
DNA Replication, Recombination, and Repair	2.68E–04–2.88E–14	41
Cell Cycle	2.14E–04–5.22E–13	104
Cell Death and Survival	2.62E–04–2.84E–12	223
Cellular Movement	2.32E–04–3.75E–12	172
Top canonical pathways affected by 5Aza
Hepatic Fibrosis / Hepatic Stellate Cell Activation	7.52E–15	16.4% 30/183
Colorectal Cancer Metastasis Signaling	8.45E–06	8.5% 21/247
Acute Phase Response Signaling	2.68E–05	9.5% 16/169
Wnt/-catenin Signaling	9.92E–05	8.9% 15/169
MIF Regulation of Innate Immunity	1.39E–04	17.1% 7/41
Diseases and disorders affected by 5Aza
Cancer	2.38E–05–2.97E–22	572
Organismal Injury and Abnormalities	2.38E–05–2.97E–22	585
Dermatological Diseases and Conditions	4.48E–08–2.42E–19	399
Gastrointestinal Disease	1.18E–05–2.84E–18	510
Metabolic Disease	1.68E–05–1.05E–12	139
Molecular and cellular functions affected by 5Aza
Cellular Movement	2.39E–05–5.26E–18	173
Cellular Development	2.30E–05–2.14E–10	219
Cellular Growth and Proliferation	2.30E–05–2.14E-10	206
Cell Morphology	1.94E-05–5.13E-10	176
Lipid Metabolism	2.18E–05–6.79E–10	88